Enhancing Tuberculosis Outcomes Through Counselling Incentives

By João L. Carapinha

June 5, 2026

tuberculosis counselling incentives

Tuberculosis counselling incentives that combine conditional cash transfers with structured pre- and post-test counselling are proving highly effective at overcoming socioeconomic barriers to treatment adherence. This integrated strategy reduces long-term disease transmission while requiring only modest additional investment from the health system, making it a practical option for high-burden settings.

By tying financial support to specific health behaviours and pairing it with targeted counselling, tuberculosis counselling incentives directly address the socioeconomic factors that drive loss to follow-up. Patients are more likely to accept treatment, complete their course, and reduce community transmission, delivering meaningful health gains without straining public budgets.

Dynamic Model Projects 25-Year Impact

Using TBMod, an age-structured mathematical model calibrated with results from a pragmatic Johannesburg trial, researchers simulated national rollout from 2025 to 2050. The model accounts for diagnosis pathways, treatment cascades, drug resistance, and transmission dynamics, projecting outcomes against a business-as-usual scenario while remaining consistent with WHO epidemiological targets.

Accelerating Averted Cases and Cost Savings

Impact builds steadily over time. After an initially modest first-year effect, reduced untreated cases curb further spread, leading to a 10.6% drop in new TB cases and 15% fewer deaths by 2050. Across the full period the intervention averts approximately 400,000 incident cases, 200,000 deaths, and 2 million disability-adjusted life years. At an incremental cost of $289 million, the programme costs $80.40 per patient treated and yields an ICER of $144 per DALY averted—well below South Africa’s $3,314 willingness-to-pay threshold. Results remained robust even when counselling and incentive costs were increased by 50%.

Strategic Value for TB Elimination Efforts

These findings, drawn from this economic evaluation, confirm that scaling tuberculosis counselling incentives is an efficient use of public resources. The approach successfully narrows persistent gaps between diagnosis and treatment completion, supporting both national and global TB reduction targets while offering clear lessons for evaluating behavioural interventions in resource-limited settings.

Reference url

Recent Posts

cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...